VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study.

This article presents the findings of a study comparing the effectiveness and tolerability of two different induction therapies for patients with newly diagnosed multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). The study found that patients who received bortezomib, lenalidomide, and dexamethasone (VRD) had higher response rates and longer progression-free survival (PFS) compared to those who received bortezomib, cyclophosphamide, and dexamethasone (VCD). VRD was also associated with a longer overall survival (OS), although the difference was not statistically significant. The study suggests that VRD should be preferred as the induction therapy for MM patients eligible for ASCT, but more research is needed to confirm these findings. [Extracted from the article]